Pentixapharm to Showcase Innovative Antibody GT-008 at AACR 2025

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, will reveal new pre-clinical data on its unique antibody, GT-008, at the AACR Annual Meeting 2025 in Chicago. Known for its glycan-dependent mechanism, GT-008 targets CD24, a protein linked with tumor growth. This innovation marks a significant step in immunotherapy and radioconjugate progress, addressing issues faced by traditional CD24 antibodies.

GT-008 demonstrates strong affinity and specificity for a cancer cell-specific O-glycoform of CD24, minimizing harm to healthy cells. This specificity lowers the chances of off-target effects, a common challenge with existing therapies. It retains binding and internalization across various tumors, including breast and ovarian cancers, with a proof-of-concept study using a radiolabeled version underway.